Cervical Cancer

P1, N=32, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2032 --> Jun 2030 | Trial primary completion date: Feb 2030 --> Jun 2029

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

An integrated immune-inflammatory phenotype combining stromal TILs and SII was independently associated with postoperative recurrence risk in cervical cancer and corresponded to distinct tissue immune states. This phenotype may provide a practical framework for recurrence risk stratification, while LASSO-Cox and RSF offer complementary prognostic perspectives.

Particular attention is given to HER2-directed antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd), which have emerged as an important recent therapeutic advance and have renewed interest in HER2 as an actionable target in selected patients with HER2-expressing cervical carcinoma. This review further highlights the need for biomarker-driven patient selection, standardized HER2 assessment, and rational integration of HER2-directed strategies into precision treatment for CC.

These resistance effects were effectively reversed by the lipogenesis inhibitor C75. Therefore, KRT6A promotes radioresistance in CESC by activating lipogenesis.

P=N/A, N=1500, Recruiting, Baylor University | Not yet recruiting --> Recruiting

These findings suggest that DEFB135, FGL2, FTMT, PDIA4, SPHK2, and TMED2 may protect against cervical cancer, while RACGAP1 may represent a potential risk factor. The identified tumor markers provide mechanistic insights into the molecular basis of cervical cancer and warrant further investigation in functional studies.

P=N/A, N=60, Enrolling by invitation, Albert Einstein College of Medicine

P4, N=5000, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Aug 2026

Nevertheless, clinical translation remains challenged by response heterogeneity attributable to tumor heterogeneity, the emergence of resistance mechanisms, and class-specific adverse events including ocular toxicity, interstitial lung disease (ILD), hepatotoxicity, and peripheral neuropathy. Continued refinement of next-generation ADC platforms - encompassing bispecific ADCs, dual-payload ADCs, peptide-drug conjugates (PDCs), and radionuclide-conjugated drugs - is anticipated to overcome current limitations and deliver superior oncologic outcomes.

Upregulation of miR-4687-3p lead to decrease in the proliferative and migratory capacity of cervical cancer cells. Target and pathway analysis supports the potential role of miR-4687-3p in several cancer related pathways. Altogether the findings suggest miR-4687-3p to be a potential therapeutic target for cervical cancer.

Instead, TFs interact with non-coding RNA and epigenetic mechanisms to form interconnected regulatory networks that promote both tumor plasticity and create potential therapeutic opportunities. Effective targeting of these networks will require biomarker-guided and rational combination strategies tailored to tumor type.